The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease. - CADET-PAD

niwersytet Jagiellonski Collegium Medicum0 个研究点目标入组 200 人开始时间: 2024年5月24日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Patients with PAOD qualified for PTAvin the Angiology Department UJ CM, with Rutherford 3 or 4 clinical symptoms., Age 45 - 75 years old., Signed informed consent., Citizen of Malopolska region

•Patients with peripheral arterial disease (PAOD) with Rutherford 1,2,5 or 6 clinical symptoms., Buerger Disease., Chronic heart failure (3-4 NYHA), Acute lower limb ischemia or surgical revascularization within last 6 months., Serious trauma or surgery procedure within last 6 months., Asthma., Ongoing antileukotriene treatment, Neoplasm diagnosed within 5 years., Chronic Kidney Disease (creat. >177 µmol/l)., Pregnancy, puerperium, women without efficient contraception., Vaccinations within 30 days before recruitment., Age < 45 or > 75 years old., Hospitalisation in intensive care unit within 3 months., Lack of the possibility of the follow-up participation., Infection and/or fever (temperature above 37,2 C) within the last 3 weeks preceding the study recruitment (viral infections, cold, sinusitis) and use of antibiotics within the last 2 months., Symptoms of acute tissue infection, Chronic inflammatory disease (e.g. COPD stage >II in GOLD classification), HIV+, HCV+, HBS+., Autoimmunological diseases and use of steroids or immunosuppressive medications within the last 3 months., Inflammatory blood vessel disorders (with exception of atherosclerosis), Myocardial infarction or stoke within last 6 months.

发起方

niwersytet Jagiellonski Collegium Medicum